

- of E7080, a multikinase inhibitor, in patients with advanced solid tumors [abstract]. *J Clin Oncol.* 2008;26(15 Suppl):14583.
- 6 Glen H, Boss D, Evans TR, et al. A phase I dose finding study of E7080 in patients (pts) with advanced malignancies [abstract]. *J Clin Oncol.* 2007;25(18 Suppl):14073.
- 7 Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit – a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. *Comput Methods Programs Biomed.* 2005;79(3):241-57.
- 8 Keizer RJ, van Benten M, Beijnen JH, et al. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. *Comput Methods Programs Biomed.* 2011;101(1):72-9.
- 9 Holford N. The visual predictive check – superiority to standard diagnostic (Rorschach) plots. In: PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe; 2005 juni 16-17; Pamplona, Spanje. Population Approach Group in Europe; 2005. [www.page-meeting.org/?abstract=738](http://www.page-meeting.org/?abstract=738).
- 10 Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. *Clin Pharmacol Ther.* 1979;25(3):358-71.
- 11 Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. *J Pharmacokinetic Biopharm.* 1993;21(4):457-78.
- 12 Dansirikul C, Silber HE, Karlsson MO. Approaches to handling pharmacodynamic baseline responses. *J Pharmacokinetic Pharmacodyn.* 2008;35(3):269-83.
- 13 Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. *J Clin Oncol.* 2005;23(4):792-9.
- 14 Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. *Am J Kidney Dis.* 2007;49(2):186-93.
- 15 Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. *Lancet Oncol.* 2008;9(2):117-23.
- 16 Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. *Acta Oncol.* 2009;48(1):9-17.
- 17 Steeghs N, Gelderblom H, Roodt JO, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. *Clin Cancer Res.* 2008;14(11):3470-6.
- 18 Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. *J Clin Oncol.* 2006;24(9):1363-9.
- 19 Keizer R. Pharmacometrics in early clinical drug development [dissertatie]. Utrecht: Universiteit Utrecht; 2010.
- 20 Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis.* 2004;43(5 Suppl 1):S1-290.
- 21 Sawyer N, Wadsworth J, Wijnen M, Gábriel R. Prevalence, concentration, and prognostic importance of proteinuria in patients with malignancies. *BMJ.* 1988;296(6632):1295-8.
- 22 Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. *Nephrol Dial Transplant.* 1995;10(11):1963-74.
- 23 ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. *Ann Intern Med.* 2001;134(5):370-9.

## Dankbetuiging

Bij de beoordeling van artikelen voor het *PW Wetenschappelijk Platform* kon de Redactieraad zich ook in 2011 weer laten adviseren door vele deskundigen uit het veld. De Redactieraad wil deze adviseurs danken voor hun bijdrage aan de kwaliteit van het *PW Wetenschappelijk Platform*. In het afgelopen jaar hebben de volgende personen zich hiervoor ingezet:

dr. A.F.Y. Al Hadithy  
 dr. A.T.G. Blom  
 dr. H.B.B. Colen  
 dr. L.G.M. Daenen  
 dr. P.H. van Erp  
 dr. R.J.E. Grouls  
 dr. A.M. Hövels  
 dr. A.D.R. Huitema  
 dr. R.G. IJzerman  
 drs. L. de Jonge

drs. P.N.J. Langendijk  
 dr. W. Meijer  
 prof. dr. J.G.R. de Monchy  
 drs. R. Oosting  
 drs. A.M.A. Prins  
 drs. C.C.M. Stuijt  
 dr. E.L. Swart  
 dr. K. Taxis  
 dr. D.J. Touw  
 dr. T.F.J. Tromp

prof. dr. D.R.A. Uges  
 drs. E.C. Vasbinder  
 prof. dr. H.M.W. Verheul  
 drs. I. de Vries  
 drs. A.G.W. te Winkel  
 dr. R.A. Winkens

*Dankbetuiging. PW Wetenschappelijk Platform. 2012;6:e1203.*